➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Baxter
Express Scripts
Mallinckrodt
Moodys

Last Updated: February 26, 2021

DrugPatentWatch Database Preview

Litigation Details for FRESENIUS KABI USA, LLC v. FERA PHARMACEUTICALS, LLC (D.N.J. 2015)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in FRESENIUS KABI USA, LLC v. FERA PHARMACEUTICALS, LLC
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for FRESENIUS KABI USA, LLC v. FERA PHARMACEUTICALS, LLC (D.N.J. 2015)

Date Filed Document No. Description Snippet Link To Document
2016-09-20 327 harma”).’ The patents-in-suit are Patent Nos. 9,006,289 (“the ‘289 patent” … — “289 Patent” United States Patent No. 9,006,289, P1. Ex. 1 (ECF No. …of the 4 (See, e.g., ‘289 Patent Claim 1; ‘238 Patent Claim 1; ‘239 Patent buffer. …’s construction of key patent terms following a Markman hearing. This patent infringement case is brough…PageID: 7183 (“the ‘238 patent”), and 9,168,239 (“the ‘239 patent”). External link to document
2016-09-20 328 is for patent infringement. The patents-in-suit are Patent Nos. 9,006,289 (“the ‘289 patent”), 9,168,238…253- 4)). “‘289 Patent” — United States Patent No. 9,006,289, P1. Ex. 1 (ECF No. 187—2)…limited patent monopoly. Where the patent holder is acting within the lawful scope of its patent, public…9,168,238 (“the ‘238 patent”), and 9,168,239 (“the ‘239 patent”). All three describe formulations of levothyroxine…2). “238 Patent” — United States Patent No. 9,168,238, P1. Ex. 2 (ECF No. 187—3). External link to document
2016-09-23 333 is for patent infringement. The patents-in-suit are Patent Nos. 9,006,289 (“the ‘289 patent”), 9,168,238…253- 4)). “289 Patent” — United States Patent No. 9,006,289, P1. Ex. 1 (ECF No. 187—2)…limited patent monopoly. Where the patent holder is acting within the lawful scope of its patent, public…9,168,238 (“the ‘238 patent”), and 9,168,239 (“the ‘239 patent”). All three describe formulations of levothyroxine…2). “238 Patent” — United States Patent No. 9,168,238, P1. Ex. 2 (ECF No. 187—3). External link to document
2017-05-19 422 three of its patents: Patent Nos. 9,006,289 (“the ‘289 patent”), 9,168,238 (“the ‘238 patent”), and the …the 9,168,239 (“the ‘239 patent”). All three patents describe formulations of levothyroxine, a hormone produced…by fraudulently obtaining the patents-in-suit and bringing sham patent litigation against it and other…Fresenius duped the patent examiner into granting Fresenius the ‘289, ‘238 and ‘239 patents through fraudulent…defendant (i.e., a non-patent holder) who filed a collateral proceeding at the Patent Office, such as an External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
AstraZeneca
Mallinckrodt
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.